Patented small molecule inhibitors in the ubiquitin proteasome system
2007
Patented Small Molecule Inhibitors in the Ubiquitin Proteasome System
publication
Evidence: moderate
Author Information
Author(s): Philippe Guédat, Frédéric Colland
Primary Institution: Hybrigenics SA
Hypothesis
The ubiquitin proteasome system (UPS) can be targeted for the development of new cancer therapies through patented small molecule inhibitors.
Conclusion
Recent advances in patented proteasome inhibitors show promise for treating multiple myeloma and other cancers.
Supporting Evidence
- The approval of Velcade® (bortezomib) for multiple myeloma treatment establishes the UPS as a valid cancer target.
- NPI-0052 has shown to outperform bortezomib in preclinical studies.
- New classes of proteasome inhibitors are being developed with potential applications in various diseases.
Takeaway
Scientists are finding new ways to stop cancer by using special drugs that target a system in our cells that helps break down proteins.
Methodology
The review assesses advances in the discovery and development of patented small-molecule inhibitors targeting components of the UPS.
Limitations
The review does not consider patents on methods or target validation in the UPS.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website